For convenience and branding purposes, this website may refer to SpadeRX or Spade Rx. Unless otherwise indicated, all references to SpadeRX, Spade Rx, we, us, or our refer to Spade RX, PC, the professional medical corporation responsible for providing medical services through this platform
Semaglutide is already listed on the Ontario drug formulary a list of publicly covered medications for those over age 65, people living in long-term care homes, and for people receiving Ontario Works or disability payments
These efforts have led to the development of various GLP-1 receptor agonists, the most recent being semaglutide and tirzepatide, approved for the treatment of type 2 diabetes in 2018 and 2022, respectively
Retatrutide adds glucagon receptor activation, making it a triple agonist